CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 150 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2023. The put-call ratio across all filers is 1.13 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,672,192 | -65.6% | 971 | -99.6% | 0.32% | -81.8% |
| Q1 2023 | $7,773,732 | -34.8% | 216,057 | -19.2% | 1.76% | -38.7% |
| Q4 2022 | $11,921,406 | +33.6% | 267,476 | -15.7% | 2.88% | +61.8% |
| Q3 2022 | $8,924,000 | -80.1% | 317,476 | -80.9% | 1.78% | -78.2% |
| Q2 2022 | $44,788,000 | -11.0% | 1,661,158 | +12.4% | 8.17% | +23.4% |
| Q1 2022 | $50,323,000 | -11.1% | 1,477,558 | +0.9% | 6.62% | -21.5% |
| Q4 2021 | $56,577,000 | -33.8% | 1,464,216 | -7.5% | 8.43% | +40.1% |
| Q3 2021 | $85,425,000 | +160.3% | 1,582,231 | +61.2% | 6.02% | +126.8% |
| Q2 2021 | $32,824,000 | +44.9% | 981,544 | -10.8% | 2.65% | +248.2% |
| Q1 2021 | $22,657,000 | -26.7% | 1,099,790 | -37.7% | 0.76% | -44.1% |
| Q4 2020 | $30,923,000 | +36.0% | 1,764,990 | +15.1% | 1.36% | -17.1% |
| Q3 2020 | $22,742,000 | -9.0% | 1,533,530 | -20.2% | 1.64% | -17.3% |
| Q2 2020 | $24,986,000 | – | 1,921,939 | – | 1.99% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 2,600,000 | $88,218,000 | 12.13% |
| Octagon Capital Advisors LP | 759,898 | $25,783,339 | 3.59% |
| TSP Capital Management Group, LLC | 251,895 | $8,546,800 | 3.08% |
| ACUTA CAPITAL PARTNERS, LLC | 122,343 | $4,151,098 | 2.81% |
| 5AM Venture Management, LLC | 310,270 | $10,527,461 | 2.62% |
| COMMODORE CAPITAL LP | 631,665 | $21,432,393 | 2.41% |
| RTW INVESTMENTS, LP | 3,463,201 | $117,506,410 | 2.24% |
| Eversept Partners, LP | 785,740 | $26,660,158 | 2.23% |
| Redmile Group, LLC | 1,696,004 | $57,545,416 | 2.21% |
| Affinity Asset Advisors, LLC | 87,031 | $2,952,962 | 1.03% |